Wire · operational-macro
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 November 2026 · Fusion42 review
The FDA approved asundexian, the first oral factor XIa inhibitor, to reduce the risk of recurrent stroke in adults after mild-to-moderate noncardioembolic ischemic stroke or high-risk transient ischemic attack. This approval follows the phase 3 OCEANIC-STROKE trial demonstrating a 26% reduction in recurrent ischemic stroke risk without increased major bleeding.
This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 9 Nov 2026 and 19 Nov 2026.
◆ ◆ The Wire takeaway
Stroke treatment founders can now focus on integrating factor XIa inhibition asundexian into post-stroke care, carving out new opportunities in stroke recurrence reduction. You must revise your pipeline to include this oral inhibitor as a competitive must-have or risk losing share to Bayer's newly approved drug.
◆ Coverage
15 sources · first reported 9 Nov 2026 · latest 19 Nov 2026
◆ Related on Wire
◆ Topics